LB 100

Drug Profile

LB 100

Alternative Names: LB-1; LB-100

Latest Information Update: 30 Jun 2017

Price : $50

At a glance

  • Originator Lixte Biotechnology Holdings
  • Developer INSERM; Lixte Biotechnology Holdings
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Phosphoprotein phosphatase inhibitors; Protein phosphatase 2A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Depressive disorders; Glioblastoma; Haematological disorders
  • Research Ischaemia

Most Recent Events

  • 30 Jun 2017 LB 100 is still in early research stage for Ischaemia in USA (Lixte pipeline, June 2017)
  • 29 Mar 2017 Lixte Biotechnology Holdings has patent protection for LB-100 and LB-200 series compounds for the prevention and treatment of Neurodegenerative disorders in USA and Australia
  • 29 Mar 2017 Lixte Biotechnology Holdings has patent protection for LB-100 in combination with anti-cancer agents in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top